| Followers | 7 |
| Posts | 5499 |
| Boards Moderated | 0 |
| Alias Born | 09/11/2013 |
Wednesday, February 21, 2018 4:18:23 PM
I'd like to offer a few original thoughts on this whole affair...
It's not like the Quarterly report or its summaries have illustrated how soon NNVC is going to get into actual Tox testing, or who the new CEO is and what skills he/she might bring, or exactly how/when the next capital raise is going to have to happen.
We're almost exactly where we were a couple of days ago - except for a cryptic statement or two about having received verbal toxicity testing summaries, that the company is still burning through their existing capital, and that they still think that they have enough production capacity to do the next stages of work.
We still don't know some important things,... and the only somewhat surprising bit of information was that Dr. Seymour is stepping down to be replaced by somebody to carry the baton through the next stage of the race.
As I have said any number of times,... this company's value and the value of its stocks will go up, and stay up consistently only when there is a good reason for it to do so.
These reasons will be obvious steps forward into FDA review, Tox testing, and entry into Clinical testing. Until then - this stock will not be consistently advancing.
It's not like the Quarterly report or its summaries have illustrated how soon NNVC is going to get into actual Tox testing, or who the new CEO is and what skills he/she might bring, or exactly how/when the next capital raise is going to have to happen.
We're almost exactly where we were a couple of days ago - except for a cryptic statement or two about having received verbal toxicity testing summaries, that the company is still burning through their existing capital, and that they still think that they have enough production capacity to do the next stages of work.
We still don't know some important things,... and the only somewhat surprising bit of information was that Dr. Seymour is stepping down to be replaced by somebody to carry the baton through the next stage of the race.
As I have said any number of times,... this company's value and the value of its stocks will go up, and stay up consistently only when there is a good reason for it to do so.
These reasons will be obvious steps forward into FDA review, Tox testing, and entry into Clinical testing. Until then - this stock will not be consistently advancing.
"Who would claim to be one who was not?"
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
